Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus rating of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.17.

A number of equities analysts have issued reports on the stock. Piper Jaffray Companies set a $19.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Finally, Jefferies Group reiterated a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 6th.

In related news, insider Alison B. Fleming sold 4,601 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total value of $79,367.25. Following the completion of the sale, the insider now directly owns 28,513 shares in the company, valued at $491,849.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CTO Alison B. Fleming sold 4,029 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total transaction of $68,493.00. Following the completion of the sale, the chief technology officer now owns 28,513 shares of the company’s stock, valued at $484,721. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,630 shares of company stock valued at $924,360. Insiders own 25.76% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. grew its holdings in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,163 shares during the period. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical during the second quarter worth approximately $125,000. Credit Suisse AG grew its stake in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the period. UBS Group AG grew its stake in Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares during the period. Finally, Nationwide Fund Advisors grew its stake in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares during the period. Hedge funds and other institutional investors own 79.98% of the company’s stock.

Collegium Pharmaceutical (NASDAQ COLL) opened at $17.00 on Monday. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm’s quarterly revenue was up 2814.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.13) earnings per share. equities analysts anticipate that Collegium Pharmaceutical will post -2.56 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-given-consensus-recommendation-of-buy-by-brokerages/1742709.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.